Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 19 of 19 entries
View as:

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Phase: N/A Priority: Normal
NCT ID: NCT05006885 Org: User:
Start: 09/30/21 End: 08/17/22 Due: 08/17/23

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Phase: N/A Priority: Normal
NCT ID: NCT04679909 Org: User:
Start: 02/25/21 End: 12/21/22 Due: 12/21/23

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Phase: N/A Priority: Normal
NCT ID: NCT03232567 Org: User:
Start: 09/18/17 End: 06/15/18 Due: 06/15/19

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Phase: N/A Priority: Normal
NCT ID: NCT04684914 Org: User:
Start: 12/26/20 End: 04/17/24 Due: 04/17/25

Study of the Safety and Immunogenicity of NasoVAX Extension

Phase: N/A Priority: Normal
NCT ID: NCT03760549 Org: User:
Start: 01/21/19 End: 02/18/19 Due: 02/18/20

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04442230 Org: User:
Start: 10/10/20 End: 02/15/21 Due: 02/15/22

Immune Response Following Seasonal Influenza Vaccination

Phase: N/A Priority: Normal
NCT ID: NCT03163342 Org: User:
Start: 05/08/17 End: 06/15/18 Due: 06/15/19

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Phase: N/A Priority: Normal
NCT ID: NCT00755703 Org: User:
Start: 10/31/08 End: 12/31/11 Due: 12/31/12

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Phase: N/A Priority: Normal
NCT ID: NCT07009860 Org: User:
Start: 07/01/25 End: 08/31/27 Due: 08/31/28

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT05989711 Org: User:
Start: 07/27/23 End: 12/30/25 Due: 12/30/26

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT02496897 Org: User:
Start: 07/31/15 End: 06/05/18 Due: 06/05/19

RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Phase: N/A Priority: Normal
NCT ID: NCT06987513 Org: User:
Start: 05/15/25 End: 09/30/26 Due: 09/30/27

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase: N/A Priority: Normal
NCT ID: NCT05134662 Org: User:
Start: 02/01/22 End: 03/09/23 Due: 03/09/24

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04972396 Org: User:
Start: 09/15/21 End: 05/15/22 Due: 05/15/23

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

Phase: N/A Priority: Normal
NCT ID: NCT04561245 Org: User:
Start: 11/10/20 End: 10/29/21 Due: 10/29/22

NasoShield Study of Safety and Immunogenicity

Phase: N/A Priority: Normal
NCT ID: NCT03352466 Org: User:
Start: 01/18/18 End: 05/13/19 Due: 05/13/20

NasoShield in Healthy Adults to Study Safety and Immunogenicity

Phase: N/A Priority: Normal
NCT ID: NCT04415749 Org: User:
Start: 06/15/20 End: 03/15/21 Due: 03/15/22

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Phase: N/A Priority: Normal
NCT ID: NCT05292911 Org: User:
Start: 03/09/22 End: 10/31/22 Due: 10/31/23

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Phase: N/A Priority: Normal
NCT ID: NCT05295875 Org: User:
Start: 03/31/22 End: 09/28/23 Due: 09/28/24